Hyderabad News Desk

(Albany, United States) As per DelveInsight’s assessment, globally, the Generalized Anxiety Disorder Pipeline constitutes 10+ key companies continuously working towards developing 12+ Generalized Anxiety Disorder Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Generalized Anxiety Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Generalized Anxiety Disorder NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Generalized Anxiety Disorder Pipeline treatment landscape of the report, click here @ Generalized Anxiety Disorder Pipeline Outlook

Key Takeaways from the Generalized Anxiety Disorder Pipeline Report

• DelveInsight’s Generalized Anxiety Disorder Pipeline analysis depicts a robust space with 10+ active players working to develop 12+ pipeline treatment therapies.
• The leading companies working in the Generalized Anxiety Disorder market include Tilray, Mind Medicine Inc., PSY Therapeutics, Pear Therapeutics, Engrail Therapeutics, Bionomics, Sage Therapeutics, Seed Health, OWP Pharmaceuticals, and others.
• Promising Generalized Anxiety Disorder Pipeline Therapies in the various stages of development include Vortioxetine, Duloxetine, SEP-363856, Troriluzole, Vilazodone, ABBV-932, and others.
• On April 2023, AbbVie announced a study of phase 1 clinical trials for ABBV-932. The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.
• On June 2023, Sumitomo Pharma America Inc. announced a study of phase 2 & 3 clinical trials for SEP-363856. A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.

Generalized Anxiety Disorder Overview

 Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues.

For further information, refer to the detailed Generalized Anxiety Disorder Unmet Needs, click here for Generalized Anxiety Disorder Ongoing Clinical Trial Analysis

Generalized Anxiety Disorder Emerging Drugs Profile

• MM-120: Mind Medicine, Inc.
• ENX-102: Engrail therapeutics

Generalized Anxiety Disorder Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the mid to advanced stage, i.e. Phase II include, Mind Medicine, Inc.

Request a sample and discover the recent advances in Generalized Anxiety Disorder Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Generalized Anxiety Disorder Segmentation

Generalized Anxiety Disorder Drugs and Companies

• Vortioxetine: Takeda
• Duloxetine: H. Lundbeck A/S
• SEP-363856: Sumitomo Pharma America Inc.

Generalized Anxiety Disorder Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type 

Some of the Companies in the Generalized Anxiety Disorder Therapeutics Market include-

Tilray, Mind Medicine Inc., PSY Therapeutics, Pear Therapeutics, Engrail Therapeutics, Bionomics, Sage Therapeutics, Seed Health, OWP Pharmaceuticals, and others.

Dive deep into rich insights for drugs for the Generalized Anxiety Disorder Pipeline, Click here @ Generalized Anxiety Disorder Unmet Needs and Analyst Views

Scope of the Generalized Anxiety Disorder Pipeline Report

• Coverage- Global
• Companies- Tilray, Mind Medicine Inc., PSY Therapeutics, Pear Therapeutics, Engrail Therapeutics, Bionomics, Sage Therapeutics, Seed Health, OWP Pharmaceuticals, and others.
• Therapies- Vortioxetine, Duloxetine, SEP-363856, Troriluzole, Vilazodone, ABBV-932, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Generalized Anxiety Disorder Merger and acquisitions, Licensing Activities

Table of Content

1. Introduction
2. Executive Summary
3. Generalized Anxiety Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Generalized Anxiety Disorder – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MM-120: Mind Medicine, Inc.
12. Drug profiles in the detailed report…..
13. Preclinical Stage Products
14. PSY-05: PSY Therapeutics
15. Drug profiles in the detailed report…..
16. Discovery Stage Products
17. Pear-011: Pear Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Generalized Anxiety Disorder – Collaborations Assessment- Licensing / Partnering / Funding
21. Generalized Anxiety Disorder – Unmet Needs
22. Generalized Anxiety Disorder – Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market